Atozet (ezetimibe/atorvastatin) vs Ezetimibe/simvastatin (Vytorin)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Atherosclerotic Cardiovascular Disease

Shared mechanism: HMG-CoA reductase / NPC1L1 · full Atherosclerotic Cardiovascular Disease pipeline

Atozet (ezetimibe/atorvastatin)

Rights held by Organon and partners; US product discontinued

small molecule combination
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

No aligned efficacy figure on record for this race.

Ezetimibe/simvastatin (Vytorin)

Marketed by Organon

Approved in Atherosclerotic Cardiovascular Diseasesmall molecule combination
Reliable signal

NCT00202878 · Phase 3 · completed

The trial randomly assigned 18,144 participants to Vytorin or simvastatin, used triple blinding, and included an active comparator. Its primary clinical endpoint occurred in 32.72% of the Vytorin group versus 34.67% of the simvastatin group; the difference was statistically significant (hazard ratio 0.936, 95% CI 0.887–0.988; p=0.016).

Reported efficacy

Time to First Occurrence of Cardiovascular Death, Major Coronary Event, or Non-fatal Stroke (Kaplan-Meier Estimate of Percentage of Participants Experiencing a Qualifying Event) (Up to approximately 9 years): Time to First Occurrence of Cardiovascular Death, Major Coronary Event, or Non-fatal Stroke (Kaplan-Meier Estimate of Percentage of Participants Experiencing a Qualifying Event) (Up to approximately 9 years): Ezetimibe/Simvastatin 32.72% (95% CI 31.63 to 33.85) vs Simvastatin 34.67% (95% CI 33.56 to 35.81) (met)

Result source: NCT00202878

Results for Atherosclerotic Cardiovascular Disease

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointAtozet (ezetimibe/​atorvastatin)Ezetimibe/​simvastatin (Vytorin)
LDL-C, % change-49.0% vs -27.8%vs Atorvastatinwk 6 · n 65NCT05761444
1 other result
  • -50.4% vs -34.4% wk 12 · n 60 · Phase 4 · secondary NCT05761444
-49.3% vs -38.0%vs Atorvastatin10/20 mg · wk 8 · n 124NCT00496730
3 other results
  • -44.7% vs -27.1% 10/80 mg divided into 4 · wk 6 · n 14 · Phase 4 · primary NCT00762164
  • -53.6% vs -38.3% ezetimibe/simvastatin 10/20mg · wk 6 · Phase 3 · primary NCT00110435
  • -57.6% vs -50.9% ezetimibe/simvastatin 10/40mg · wk 6 · Phase 3 · primary NCT00110435
Non-HDL-C, % change—Not reported—Not posted · NCT00110435
ApoB, % change—Not reported—Not posted · NCT00110435
Lp(a), % change—Not reported—Not posted · NCT00110435
3-point MACE (% with event)—Not reported—Not posted · NCT00110435

LDL-C, % change

Atozet (ezetimibe/​atorvastatin)
-49.0% vs -27.8%vs Atorvastatinwk 6 · n 65NCT05761444
1 other result
  • -50.4% vs -34.4% wk 12 · n 60 · Phase 4 · secondary NCT05761444
Ezetimibe/​simvastatin (Vytorin)
-49.3% vs -38.0%vs Atorvastatin10/20 mg · wk 8 · n 124NCT00496730
3 other results
  • -44.7% vs -27.1% 10/80 mg divided into 4 · wk 6 · n 14 · Phase 4 · primary NCT00762164
  • -53.6% vs -38.3% ezetimibe/simvastatin 10/20mg · wk 6 · Phase 3 · primary NCT00110435
  • -57.6% vs -50.9% ezetimibe/simvastatin 10/40mg · wk 6 · Phase 3 · primary NCT00110435

Non-HDL-C, % change

Atozet (ezetimibe/​atorvastatin)
—Not reported
Ezetimibe/​simvastatin (Vytorin)
—Not posted · NCT00110435

ApoB, % change

Atozet (ezetimibe/​atorvastatin)
—Not reported
Ezetimibe/​simvastatin (Vytorin)
—Not posted · NCT00110435

Lp(a), % change

Atozet (ezetimibe/​atorvastatin)
—Not reported
Ezetimibe/​simvastatin (Vytorin)
—Not posted · NCT00110435

3-point MACE (% with event)

Atozet (ezetimibe/​atorvastatin)
—Not reported
Ezetimibe/​simvastatin (Vytorin)
—Not posted · NCT00110435
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Atozet (ezetimibe/atorvastatin): 4 of 4 rows · Ezetimibe/simvastatin (Vytorin): 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricAtozet (ezetimibe/​atorvastatin)Ezetimibe/​simvastatin (Vytorin)
Dropout rate
11.9%
NCT05761444 · Phase 4 · registry result, not featured evidence · Atherosclerotic Cardiovascular Disease · phase 4
24.3%Ezetimibe/Simvastatina
NCT00202878 · Phase 3 · Atherosclerotic Cardiovascular Disease · phase 3
show 5 more results
—Ezetimide/Simvastatin
NCT00202878 · Phase 3 · Atherosclerotic Cardiovascular Disease · phase 3
4.6%10/20 mg
NCT00496730 · Phase 3 · Atherosclerotic Cardiovascular Disease · phase 3
12.1%10/20 mg
NCT00654628 · Phase 4 · registry result, not featured evidence
17.6%10/80 mg divided into 4
NCT00762164 · Phase 4 · registry result, not featured evidence
14.4%
NCT00442897 · Phase 4 · registry result, not featured evidence
Discontinued due to AEs
3%
NCT05761444 · Phase 4 · registry result, not featured evidence · Atherosclerotic Cardiovascular Disease · phase 4
—Ezetimibe/Simvastatina
NCT00202878 · Phase 3 · Atherosclerotic Cardiovascular Disease · phase 3
show 5 more results
—Ezetimide/Simvastatin
NCT00202878 · Phase 3 · Atherosclerotic Cardiovascular Disease · phase 3
—10/20 mg
NCT00496730 · Phase 3 · Atherosclerotic Cardiovascular Disease · phase 3
5.2%10/20 mg
NCT00654628 · Phase 4 · registry result, not featured evidence
—10/80 mg divided into 4
NCT00762164 · Phase 4 · registry result, not featured evidence
0.8%
NCT00442897 · Phase 4 · registry result, not featured evidence
Serious AEs
6%
NCT05761444 · Phase 4 · registry result, not featured evidence · Atherosclerotic Cardiovascular Disease · phase 4
—Ezetimibe/Simvastatina
NCT00202878 · Phase 3 · Atherosclerotic Cardiovascular Disease · phase 3
show 5 more results
40.1%Ezetimide/Simvastatin
NCT00202878 · Phase 3 · Atherosclerotic Cardiovascular Disease · phase 3
—10/20 mg
NCT00496730 · Phase 3 · Atherosclerotic Cardiovascular Disease · phase 3
0.6%10/20 mg
NCT00654628 · Phase 4 · registry result, not featured evidence
0%10/80 mg divided into 4
NCT00762164 · Phase 4 · registry result, not featured evidence
0%
NCT00442897 · Phase 4 · registry result, not featured evidence
Most frequent reported AEs
alanine aminotransferase increased 1.5%
alopecia 1.5%
anaemia 1.5%
NCT05761444 · Phase 4 · registry result, not featured evidence · Atherosclerotic Cardiovascular Disease · phase 4
a
arthralgia 11%
myalgia 10.5%
pain in extremity 10.5%
NCT00202878 · Phase 3 · Atherosclerotic Cardiovascular Disease · phase 3
show 4 more results
10/20 mg
hypercholesterolaemia 4.8%
hypertriglyceridaemia 3.2%
abdominal pain upper 1.6%
NCT00496730 · Phase 3 · Atherosclerotic Cardiovascular Disease · phase 3
10/20 mg
myalgia 4%
upper respiratory infection 4%
increased creatine phosphokinase (cpk) 3.5%
NCT00654628 · Phase 4 · registry result, not featured evidence
10/80 mg divided into 4
muscle pain-myalgia 11.8%
NCT00762164 · Phase 4 · registry result, not featured evidence
upper respiratory tract infection 3.7%
headache 1.9%
transaminases increased 1.9%
NCT00442897 · Phase 4 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for 3 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Atozet (ezetimibe/atorvastatin)

LDL-C Less Than 55 46.2% (n=65) vs 9% (n=67) Atorvastatin @ 6wk
responder rate · % of participants
NCT05761444 · Phase 4 · registry result, not featured evidence · Atherosclerotic Cardiovascular Disease · phase 4
show 1 more result
55% (n=65) vs 15.4% (n=67) Atorvastatin @ 12wk
NCT05761444 · Phase 4 · registry result, not featured evidence · Atherosclerotic Cardiovascular Disease · phase 4
LDL-C Less Than 70 78.5% (n=65) vs 38.8% (n=67) Atorvastatin @ 6wk
responder rate · % of participants
NCT05761444 · Phase 4 · registry result, not featured evidence · Atherosclerotic Cardiovascular Disease · phase 4
show 1 more result
85% (n=65) vs 58.5% (n=67) Atorvastatin @ 12wk
NCT05761444 · Phase 4 · registry result, not featured evidence · Atherosclerotic Cardiovascular Disease · phase 4

Ezetimibe/simvastatin (Vytorin)

CV Death MI or Stroke Composite 32.72% (n=9067) vs 34.67% (n=9077) Simvastatin
responder rate · % of participants
NCT00202878 · Phase 3 · Atherosclerotic Cardiovascular Disease · phase 3
All-Cause Death MI or Stroke Composite 38.65% (n=9067) vs 40.25% (n=9077) Simvastatin
responder rate · % of participants
NCT00202878 · Phase 3 · Atherosclerotic Cardiovascular Disease · phase 3
CHD Death/Non-fatal MI or Urgent Revascularization Composite 17.52% (n=9067) vs 18.88% (n=9077) Simvastatin
responder rate · % of participants
NCT00202878 · Phase 3 · Atherosclerotic Cardiovascular Disease · phase 3
CV Death MI UA Revascularization or Stroke Composite 34.49% (n=9067) vs 36.2% (n=9077) Simvastatin
responder rate · % of participants
NCT00202878 · Phase 3 · Atherosclerotic Cardiovascular Disease · phase 3
LDL-C Goal Attainment 84.7% (n=124) vs 76.9% (n=121) Atorvastatin @ 8wk10/20 mg
event count · % of participants
NCT00496730 · Phase 3 · Atherosclerotic Cardiovascular Disease · phase 3 · converted to % from 105 Participants attaining LDL-C goal as posted
LDL-C Goal Attainment 90.4% (n=115) @ 6wk10/20 mg
responder rate · % of participants
No placebo or comparator arm
NCT00654628 · Phase 4 · registry result, not featured evidence
show 1 more result
87.8% (n=49) @ 12wk10/20 mg
NCT00654628 · Phase 4 · registry result, not featured evidence
LDL-C -51.4% (n=152) @ 6wk10/20 mg
percent change · % of baseline
No placebo or comparator arm
NCT00654628 · Phase 4 · registry result, not featured evidence
show 1 more result
-53.8% (n=55) @ 12wk10/20 mg
NCT00654628 · Phase 4 · registry result, not featured evidence
Total Cholesterol -38.1% (n=152) @ 6wk10/20 mg
percent change · % of baseline
No placebo or comparator arm
NCT00654628 · Phase 4 · registry result, not featured evidence
show 1 more result
-39.5% (n=55) @ 12wk10/20 mg
NCT00654628 · Phase 4 · registry result, not featured evidence
HDL-C 4.5% (n=152) @ 6wk10/20 mg
percent change · % of baseline
No placebo or comparator arm
NCT00654628 · Phase 4 · registry result, not featured evidence
show 1 more result
9.4% (n=55) @ 12wk10/20 mg
NCT00654628 · Phase 4 · registry result, not featured evidence
Triglycerides -22.2% (n=152) @ 6wk10/20 mg
percent change · % of baseline
No placebo or comparator arm
NCT00654628 · Phase 4 · registry result, not featured evidence
show 1 more result
-24.7% (n=55) @ 12wk10/20 mg
NCT00654628 · Phase 4 · registry result, not featured evidence
LDL-C -82 mg/dL @ 6wk10/20 mg
absolute change · mg/dL
No placebo or comparator arm
NCT00654628 · Phase 4 · registry result, not featured evidence
show 1 more result
-85.6 mg/dL @ 12wk10/20 mg
NCT00654628 · Phase 4 · registry result, not featured evidence
Total Cholesterol -34.2% (n=14) vs -19.9% (n=15) Simvastatin @ 6wk10/80 mg divided into 4
percent change · % of baseline
NCT00762164 · Phase 4 · registry result, not featured evidence

+ 1 further endpoint in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Atozet (ezetimibe/atorvastatin)'s landscape · Ezetimibe/simvastatin (Vytorin)'s landscape